Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Momenta Pharmaceuticals Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Momenta Pharmaceuticals Inc (MNTA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2020
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
27.56 %
Q2 2020
Net Margin
-862.81 %
Q2 2020

Key Findings: Momenta Pharmaceuticals Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 30M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is decelerating (-12.1% annualized vs trailing 12 months).
  • Peer revenue share: Momenta Pharmaceuticals Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

MNTA Sales vs. its Competitors, Q2 2020

Momenta Pharmaceuticals Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MNTA/competitors
https://api.csimarket.com/api/v1/companies/MNTA/relationships
https://api.csimarket.com/api/v1/companies/MNTA/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API

For context: the Biotechnology & Pharmaceuticals industry grew revenue 21.4% year over year, combined, vs 27.6% for Momenta Pharmaceuticals Inc. Momenta Pharmaceuticals Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.

Momenta Pharmaceuticals Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Momenta Pharmaceuticals inc - No No No
High-Confidence Competitors (133) 44% 63% 43% 52%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q2 2020

100%market share
  • Momenta Pharmaceuticals Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Momenta Pharmaceuticals Inc and its 0 tracked competitors.

See Momenta Pharmaceuticals Inc's full market share breakdown »

MNTA Stock Performance relative to its Competitors

MNTA Competitors (weighted) Percent change over the selected range

Momenta Pharmaceuticals Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
35.1%beat U.S.A. 500
High-Confidence
(39 of 111)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Momenta Pharmaceuticals inc - -
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (111) 40.4% 63.2%
Similar-Size Competitors (0) 40.4% 63.2%
Similar Growth & Profitability (0) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Momenta Pharmaceuticals Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

MNTA Stock Performance relative to High-Confidence Competitors

MNTA High-Confidence Competitors (equal-weighted, 138) Percent change over the selected range

Momenta Pharmaceuticals Inc's Competitors Named by the Company

Competitive relationships identified from Momenta Pharmaceuticals Inc reports and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Medtronic plc Company report 85% 2022 to 2026 3
Boston Scientific Corporation Company report 85% 2022 to 2026 3
Angiodynamics Inc Company report 85% 2022 to 2026 3
Intuitive Surgical Inc Company report 85% 2022 to 2026 3
Abbvie Inc Company report 85% 2022 to 2026 3
Encision Inc Company report 85% 2022 to 2026 3
Abbott Laboratories Company report 85% 2022 to 2026 3
United Health Products Inc Company report 85% 2022 to 2026 3
Co diagnostics Inc Company report 85% 2022 to 2026 3
Catheter Precision Inc Company report 85% 2022 to 2026 3
Integra Lifesciences Holdings Corp Company report 85% 2022 to 2026 3
Globus Medical Inc Company report 85% 2022 to 2026 3
Bioventus Inc Company report 85% 2022 to 2026 3
Koninklijke Philips Nv Company report 85% 2022 to 2026 3
Acutus Medical Inc Company report 85% 2022 to 2026 3
Novavax inc Company report 85% 2022 to 2026 3
Cardiovascular Systems, Inc. Company report 85% 2022 to 2026 3
Inspiremd Inc Company report 85% 2022 to 2026 3
Briacell Therapeutics Corp Company report 85% 2022 to 2026 3
Acumen Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Stryker Corp Company report 85% 2022 to 2026 3
Voyager Therapeutics Inc Company report 85% 2022 to 2026 3
Enovis Corp Company report 85% 2022 to 2026 3
Biodexa Pharmaceuticals Plc Company report 85% 2022 to 2026 3
Black Diamond Therapeutics Inc Company report 85% 2022 to 2026 3
Monogram technologies inc Company report 85% 2022 to 2026 3
Bristol myers Squibb Company Company report 85% 2022 to 2026 3
Vanda Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Paragon 28 inc Company report 85% 2022 to 2026 3
Addex Therapeutics Ltd Company report 85% 2022 to 2026 3
Mersana Therapeutics inc Company report 85% 2022 to 2026 3
Sutro Biopharma Inc Company report 85% 2022 to 2026 3
Apexigen Inc Company report 85% 2022 to 2026 3
Morphic Holding inc Company report 85% 2022 to 2026 3
Sellas Life Sciences Group Inc Company report 85% 2022 to 2026 3
Agentix Corp Company report 85% 2022 to 2026 3
Tempest Therapeutics Inc Company report 85% 2022 to 2026 3
Oragenics Inc Company report 85% 2022 to 2026 3
Curanex Pharmaceuticals Inc Company report 85% 2022 to 2026 3
Ss Innovations International Inc Company report 85% 2022 to 2026 3
Competitor Evidence Detail

Company report basis, confidence, active dates and source counts for Momenta Pharmaceuticals Inc's named competitors require a Commercial License.

Methodology: relationships are extracted from Momenta Pharmaceuticals Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.

Get the full CSIMarket dataset: Subscribe API Connect Your AI